AXSM vs DFTX
AXSM: A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel candidates. DFTX: Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and autism.
Side-by-side fundamentals
| Metric | AXSM | DFTX | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $234.64 | $42.65 | |
| Market cap as of 2026-07-31 | $12.1B | $5.9B | |
| PEG as of 2026-07-31 | 2.51 | -0.12 | DFTX lower |
| Net margin as of 2026-07-31 | -26.6% | n/a | |
| Gross margin as of 2026-07-31 | +92.6% | n/a | |
| Operating margin as of 2026-07-31 | -25.9% | n/a | |
| ROE as of 2026-07-31 | -260.0% | -102.5% | DFTX higher |
| ROA as of 2026-07-31 | -27.8% | -70.7% | AXSM higher |
| Debt / equity as of 2026-07-31 | 3.61 | 0.15 | DFTX lower |
| Revenue growth (YoY) as of 2026-07-31 | +63.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +133.7% | n/a | |
| Beta as of 2026-07-31 | 0.67 | 2.31 | |
| 1-year return as of 2026-07-30 close | +131.7% | +337.0% | DFTX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.